Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Biomedica Share News (OXB)

Share Price Information for Oxford Biomedica (OXB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 328.00
Bid: 325.50
Ask: 330.00
Change: 28.00 (9.33%)
Spread: 4.50 (1.382%)
Open: 304.00
High: 350.00
Low: 303.00
Prev. Close: 300.00
OXB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EXECUTIVE CHANGES: Oxford BioMedica adds former Teva exec to board

Thu, 15th Jul 2021 14:54

(Alliance News) - The following is a round-up of London-listed company director and manager changes announced on Wednesday and Thursday and not separately reported by Alliance News:

----------

Mitchells & Butlers PLC - Birmingham, England-based operator of pubs, bars and restaurants - Says non-executive directors Colin Rutherford and Imelda Walsh will step down from the board on Monday next week, while Ron Robson will depart as a non-executive director on July 31. Mitchells & Butlers had announced the three departures back in May as part of a reduction in the size of its board to nine members.

----------

Salt Lake Potash Ltd - Western Australia-focused organic sulphate of potash miner - Hires Stuart Fraser as chief financial officer. Fraser most recently was chief accounting officer at oil field services firm Weatherford International, having previously worked for peer Schlumberger.

----------

Oxford BioMedica PLC - Oxford, England-based gene and cell therapy company - Hires Michael Hayden as non-executive director, starting Thursday. Hayden is a Canadian who has founded five biotechnology companies and also served as president of Global R&D & chief scientific officer at Israel-based Teva Pharmaceuticals Industries Ltd from 2012 to 2017.

----------

Everyman Media Group PLC - operates fourth largest cinema chain in UK by number of venues - Hires Maggie Todd as independent non-executive director, effective immediately. Todd was vice president of Communications for Walt Disney Studios Motion Pictures in Europe for 12 years. She also worked at Twenty Century Fox.

----------

BMO Capital & Income Investment Trust PLC - investment trust with portfolio consisting mainly of FTSE All-Share companies - Senior Independent Director Clare Dobie retires, having served on the board since 2012. Tim Scholefield appointed senior independent director in her place.

----------

Troy Income & Growth Trust PLC - invests predominantly in UK equities - Hires Brigid Sutcliffe as non-executive director, starting August 1. Sutcliffe is a chartered accounting who worked in investment banking and as a management consultant. Jann Brown will retire from the board in January, having served for nine years, and Sutcliffe will take over as chair of the Audit Committee at that time.

----------

By Tom Waite; thomaslwaite@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
28 Jan 2022 09:56

Oxford Biomedica creates venture with Homology, launches £80m fundraise

(Sharecast News) - Cell and gene therapy specialist Oxford Biomedica announced an agreement with Homology Medicines on Friday, as well as a placing to raise £80m from new and existing shareholders, including a retail offer through the PrimaryBid platform.

Read more
17 Jan 2022 09:32

Oxford Biomedica starts search for new CEO as Dawson steps down

Oxford Biomedica starts search for new CEO as Dawson steps down

Read more
17 Jan 2022 07:10

Oxford Biomedica CEO John Dawson to step down

(Sharecast News) - Oxford Biomedica chief executive John Dawson said he was stepping down after 13 years at the helm of the Gene and cell therapy firm which helped develop a Covid-19 vaccine with AstraZeneca.

Read more
5 Jan 2022 08:54

Oxford Biomedica wins new agreement for LentiVector platform

Oxford Biomedica wins new agreement for LentiVector platform

Read more
5 Jan 2022 07:29

Oxford Biomedica signs licence, supply deal with Cabaletta Bio

(Sharecast News) - Gene and cell therapy group Oxford Biomedica on Wednesday said it had signed a new license and supply agreement on its LentiVector platform with US-based Cabaletta Bio.

Read more
15 Dec 2021 09:33

LONDON BROKER RATINGS: BofA starts Pod Point at Buy; Barclays cuts DCC

LONDON BROKER RATINGS: BofA starts Pod Point at Buy; Barclays cuts DCC

Read more
13 Dec 2021 10:03

Oxford Biomedica in license and supply deals with Novartis and Arcellx

Oxford Biomedica in license and supply deals with Novartis and Arcellx

Read more
13 Dec 2021 07:31

Oxford Biomedica strikes new license and supply agreements

(Sharecast News) - Gene and cell therapy group Oxford Biomedica has struck new license and supply agreements for its lentiviral vectors.

Read more
19 Oct 2021 10:50

Oxford BioMedica licences technology for cystic fibrosis treatment

Oxford BioMedica licences technology for cystic fibrosis treatment

Read more
19 Oct 2021 09:18

Boehringer Ingelheim licenses Oxford Biomedica's lentiviral vector technology

(Sharecast News) - Gene and cell therapy firm Oxford Biomedica said on Tuesday that pharmaceutical giant Boehringer Ingelheim had exercised its option to license its lentiviral vector technology to manufacture, register and commercialise a treatment for cystic fibrosis.

Read more
30 Sep 2021 09:35

LONDON BROKER RATINGS: Keppler Cheuvreux raises Pearson to Hold

LONDON BROKER RATINGS: Keppler Cheuvreux raises Pearson to Hold

Read more
28 Sep 2021 09:40

LONDON BROKER RATINGS: Investec prefers 888 over Entain

LONDON BROKER RATINGS: Investec prefers 888 over Entain

Read more
22 Sep 2021 16:54

LONDON MARKET CLOSE: Stocks up as Evergrande fears soothed before Fed

LONDON MARKET CLOSE: Stocks up as Evergrande fears soothed before Fed

Read more
22 Sep 2021 09:16

TOP NEWS: Oxford BioMedica sales double; Serum Institute buys stake

TOP NEWS: Oxford BioMedica sales double; Serum Institute buys stake

Read more
22 Sep 2021 07:03

Oxford Biomedica swings to profit on Covid-19 vaccine sales

(Sharecast News) - Covid-19 vaccine producer Oxford Biomedica swung to a profit in the half year on the back of a surge in revenues through its partnership deal with AstraZeneca and announced that Serum Institute of India has agreed to invest £50m in the group in return for a 3.9% stake in the company.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.